drugset / Trial / NCT04590547
GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19)
RandomizedParallel-groupTriple-blindTreatment
Summary
This clinical trial will evaluate the safety, tolerability and efficacy of GLS-1027 in the prevention of severe pneumonitis caused by SARS-CoV-2 infection
Timeline
- Start
- 2021-05-07
- Primary completion
- 2022-08-14
- Completion
- 2023-07-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VGX-1027 | Small molecule | 120 mg | Oral |
| Subject | VGX-1027 | Small molecule | 360 mg | Oral |